Similar to the PBMCs of healthy volunteers, both the CD14+ and CD56+ immune effector cells in the PBMCs of breast cancer patients’ showed HER2-trogocytosis (Figure 3A) and target cell cytotoxicity (Figure 3B). The gene discussed is ERBB2; the disease is breast carcinoma.